Dolutegravir drug-drug interactions

Dolutegravir is neither an inducer nor inhibitor of metabolising enzymes, and it therefore has a low propensity to act as perpetrator drug-drug interactions. Clinically significant decreases in dolutegravir exposure occur when co-administered with strong inducers (e.g. rifampicin, efavirenz) drug enzymes efflux transporters for which substrate – this can be overcome by increasing the dose from 50 mg once daily twice daily. significantly increases metformin plasma exposure: one must not exceed 500 concomitant dolutegravir. Divalent or trivalent cations chelate Therefore, administration aluminium- calcium-containing antacids should avoided. administered calcium iron supplements, provided these are taken together food.